证券代码：603217 证券简称：元利科技 公告编号：2026-006 元利化学集团股份有限公司 关于 2025 年员工持股计划预留份额分配的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 本次员工持股计划草案披 | 时间：2025 年 8 月 28 日 | | --- | --- | | 露时间及公告名称 | 公告名称：《元利化学集团股份有限公司 2025 年员 | | | 工持股计划（草案）》 | | 本次参与对象范围及人数 | 参与对象范围：公司及控股子公司中高层管理人 | | | 员、骨干员工以及本次员工持股计划管理委员会认 | | | 为应当激励的其他员工 | | | 参与人数：不超过 7 人 | | 董事、高管参与认购情况 | 是否有董事、高管参与认购：□是 ☑否 | | 本次授予股票数量、占本期 | 本次授予股票数量：39 万股 | | 员工持股计划标的股票总 | 占本期员工持股计划标的股票总额的比例：13.54% | | 额及公司总股本的比例 | 占公司总股本的比例：0.19% | | ...

Investment Rating - The industry investment rating is "Buy" [1] Core Insights - The report highlights the rapid growth of synthetic biology, with a significant increase in the number of synthetic biology companies in Beijing's Changping District, which has surged nearly 70% compared to the same period last year, reaching a total of 146 companies [9] - The establishment of the world's largest pilot transformation platform by Huaxi Biological in Tianjin, which has a total investment of several billion yuan and spans 40,000 square meters, is a key development in the industry [10] - The National Development and Reform Commission has issued the "14th Five-Year Plan for the Development of the Bioeconomy," indicating a trillion-yuan market potential in the bioeconomy sector [4] Market Dynamics - The Huaxi Synthetic Biology Index decreased by 0.49% to 1271.82 during the week of February 24-27, 2026, underperforming compared to the Shanghai Composite Index, which rose by 1.98% [5] - The report notes that the synthetic biology sector is experiencing a wave of technological advancements and increased investment, with nearly 100 companies completing new financing rounds since 2025 [33] Company Developments - Huaxi Biological's pilot platform has already undertaken over 30 biological manufacturing projects, facilitating the transition from laboratory-scale to commercial-scale production [10] - The report mentions that Lif Biological's PEF (polyethylene furanoate) has received approval for food contact use, marking a significant step for bio-based materials in the food packaging sector [24] - Watson Biological has announced a 450 million yuan investment to establish a fund focused on synthetic biology, with a target size of 1 billion yuan [25] Industry Financing - The report indicates that financing in the synthetic biology sector is accelerating, with companies like Rhein Biological and EcoviaBio completing multiple rounds of financing to expand their production capabilities [33][34] - Rhein Biological is focusing on two main development directions: enhancing its core business and providing industrialization services for external synthetic biology products [34]

Investment Rating - The industry investment rating is "Buy" [1] Core Insights - The report highlights the rapid growth of synthetic biology, with a significant increase in the number of synthetic biology companies in Beijing's Changping District, which has surged nearly 70% compared to the same period last year, reaching a total of 146 companies [9] - The establishment of the world's largest pilot transformation platform by Huaxi Biological in Tianjin, which has a total investment of several billion yuan and spans 40,000 square meters, is a key development in the industry [10] - The "14th Five-Year Plan" for the development of the bio-economy has been issued by the National Development and Reform Commission, indicating a trillion-yuan market potential in the bio-economy sector [4] Market Dynamics - The Huaxi Synthetic Biology Index decreased by 0.49% to 1271.82 during the week of February 24-27, 2026, underperforming compared to the Shanghai Composite Index, which rose by 1.98% [5] - The report notes that the synthetic biology sector is experiencing a biotechnology revolution, providing innovative solutions to major challenges such as health, climate change, and food security [4] Company Developments - The report mentions that Watson Bio has established a 450 million yuan industry fund focused on synthetic biology, with a target size of 1 billion yuan [25] - Jin Dan Technology announced an additional investment of approximately 148 million yuan in its 75,000-ton annual production project for polylactic acid, bringing the total investment to 1.03 billion yuan [26] - The report also highlights the successful commercialization of products such as mannitol and alonose by companies like Weiyuan Synthetic [9] Industry Financing - The report indicates that financing in the synthetic biology sector is accelerating, with nearly 100 companies completing new financing rounds since 2025 [33] - EcoviaBio completed a Series B financing round to expand its production capacity for gamma-polyglutamic acid, a biodegradable material [34] - Verley, a precision fermentation company, successfully completed a $38 million Series A financing, marking a significant step towards commercializing precision fermentation [34]

Summary of Conference Call Notes Company Overview - The company discussed is Yuanli Technology, a leading enterprise in fine chemicals, specifically focusing on products such as Dimethyl 2,5-furandicarboxylate (MDBE) and 1,6-Hexanediol. Key Points - **Price Increases Announced**: On February 27, Yuanli Technology issued a price increase notice for multiple products. The price of MDBE was raised by 300 RMB per ton, while the price of 1,6-Hexanediol was increased by 500 RMB per ton [1]. - **Production Capacity**: The current production capacity for MDBE is 100,000 tons, with an additional 60,000 tons planned for future investment. For 1,6-Hexanediol, the existing capacity is 47,000 tons, with a new 30,000-ton facility under construction [2]. - **Downstream Demand**: The primary downstream application for these products is in Thermoplastic Polyurethane (TPU). On February 26, major TPU manufacturers such as Wanhua Chemical, Huafeng Thermoplastics, and Daon shares announced price increases ranging from 1,000 to 1,500 RMB per ton [3]. Additional Important Information - The price adjustments reflect the company's strategy to align with market trends and demand in the TPU sector, indicating a robust market environment for fine chemicals [1][2][3].

证券代码：603217 证券简称：元利科技 公告编号：2026-005 元利化学集团股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 81 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 136,780,965 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | 66.6549 | | 总数的比例（%） | | 本次股东会由公司董事会召集，公司董事长刘修华先生主持会议，会议采取 现场和网络投票相结合的方式表决。会议的召集、召开及表决方式符合《公司法》 (四) 表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况 等。 (一) 股东会召开的时间：2026 年 2 月 27 日 (二) 股东会召开的地点：潍坊市昌乐县朱刘街道工业园公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于元利化学集团股份有限公司 2026 年第一次临时股东会的 法律意见书 致：元利化学集团股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2026 年第一次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律 业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《元利化学集团股份 有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、 召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律 ...

Group 1: Rare Earth and Tungsten Industry - The company is one of the six major rare earth groups in the country, having completed the integration of rare earth resources in Fujian Province [2] - The company possesses a complete tungsten industry chain, with significant competitive advantages in tungsten mining, smelting, powder, wire materials, and hard alloy deep processing [2] - The company is the first in China to develop and produce ITER filter tungsten probe components for nuclear fusion devices, capable of precision machining large-sized ITER-grade tungsten materials [2] Group 2: Data Center and AI Computing - The company is planning to acquire a stake in Xiantian Computing and aims to leverage it to acquire control of Zhengzhou Heying, which focuses on third-party large-scale data center operations [3] - The company is collaborating with Alibaba Cloud to jointly invest 15.8 billion yuan in building a cloud computing data center in Zhejiang [3] - The company has established a large data center in Xinjiang Hami, with a total computing power exceeding 80,000 P [3] Group 3: Power and Energy Sector - The company has acquired Honghe Power, a major thermal power plant in southern Yunnan, with a certified installed capacity of 1,300 MW [5] - The company is a leading player in the composite insulator market for high-voltage transmission lines, with a net profit growth of 177.52% year-on-year [5] - The company is expected to achieve a profit of 300 million to 360 million yuan by 2025, marking a turnaround from previous losses [5] Group 4: Semiconductor and AI Technology - The company has developed a low-code platform that integrates AI capabilities and has been applied in various sectors including power, aerospace, and manufacturing [4] - The company is a leading domestic player in crystal oscillators, with products applicable in optical communication and navigation systems [4] - The company has launched a series of AI products and is involved in the construction of AI computing centers across the country [4] Group 5: Renewable Energy and Materials - The company is a leader in the photovoltaic aluminum frame market, with a global market share exceeding 18% [5] - The company is investing 600 million yuan to build a project for producing 10,000 tons of iron phosphate battery precursor materials annually [8] - The company has established a comprehensive lithium battery supply chain, including mining, selection, and processing of lithium carbonate [8]

Core Viewpoint - The article discusses the recent announcement of a new project by Ningxia Jiangping Biotechnology Co., Ltd. to construct a facility with an annual production capacity of 12,000 tons of bio-based dicarboxylic acids, highlighting the growing interest and activity in the bio-based dicarboxylic acid sector [1][3]. Project Overview - Ningxia Jiangping Biotechnology Co., Ltd. was established on October 14, 2025, with a registered capital of 150 million yuan. The company focuses on bio-based materials, bio-chemicals, agricultural biotechnology, and environmental technology [3]. - The specific product types for the new project are not detailed, but the focus is on the bio-based dicarboxylic acid sector, which has seen increased activity with several companies launching new projects [3]. Understanding Bio-based Dicarboxylic Acids - Bio-based dicarboxylic acids are organic compounds produced through fermentation or biomass conversion, characterized by having carboxyl groups (-COOH) at both ends of their molecular structure. They are used in various applications, including polyesters, polyamides (nylon), biodegradable plastics, lubricants, fragrances, and hot melt adhesives [4]. - They can be categorized into two main types: aliphatic dicarboxylic acids and aromatic dicarboxylic acids. Aliphatic dicarboxylic acids are further divided based on the number of carbon atoms: short-chain (C2-C4), medium-chain (C5-C9), and long-chain (≥C10) [4]. Aliphatic Dicarboxylic Acids - Short-chain dicarboxylic acids like malonic acid (C3) and succinic acid (C4) have achieved commercialization, with bio-based succinic acid being the most advanced in terms of industrialization [5][6]. - Medium-chain dicarboxylic acids such as hexanedioic acid (C6) and nonanedioic acid (C9) are also commercialized, with major producers like Cargill and Emery Oleochemicals [6]. - Long-chain dicarboxylic acids, including decanedioic acid (DC10) and dodecanedioic acid (DC12), have been industrialized, with companies like Kasei Biotech leading the market [8]. Aromatic Dicarboxylic Acids - Common bio-based aromatic dicarboxylic acids include 2,5-furandicarboxylic acid (FDCA) and terephthalic acid (PTA). China has established a strong presence in the FDCA sector, with over 10 companies involved in the industry [9]. - Internationally, Avantium is a pioneer in the FDCA field, having built a 5,000-ton commercial production line [9]. - The bio-based PTA production route involves converting bio-based naphtha to bio-based para-xylene (PX) and then to PTA, with companies like Hanwha and Taiwan Oriental Petrochemical participating in this market [9]. Industry Developments - Companies such as Jinfa Technology and Huaheng Biotechnology have launched projects to increase their production capacities of bio-based dicarboxylic acids, with Jinfa's capacity expected to reach 150,000 tons per year by December 2025 [10]. - The article also mentions the upcoming Bio-based 2026 conference, which will focus on the latest developments in bio-based chemicals and materials, providing a platform for industry collaboration [12][13].

Group 1 - The stock price of Yuanli Technology (603217) has shown a volatile trend over the past week, underperforming the market, closing at 25.28 yuan on February 13, 2026, with a daily increase of 0.40%, but a cumulative decline of 1.98% over the last five days, with a price fluctuation of 7.68% [1] - The main capital has been continuously flowing out, with a net outflow of 13.23 million yuan over the last three days, including a single-day net outflow of 6.44 million yuan on February 12, indicating low short-term capital participation [1] - The technical analysis shows that the stock price is approaching the lower support level of the 20-day Bollinger Bands at 24.78 yuan, and the MACD indicator is in a bearish zone, necessitating attention to the effectiveness of the support level in the short term [1] Group 2 - Recent developments in the new materials sector have attracted market attention, with Yuanli Technology's application of products in solid-state batteries currently in the product validation and iterative testing phase, as noted in a market analysis article on February 12 [2] - The company's recent business layout includes expanding new material technology research and development through its wholly-owned subsidiary, although the investment scale is relatively small at 5 million yuan, which does not significantly impact its financial status [2]

证券代码：603217 证券简称：元利科技 元利化学集团股份有限公司 2026 年第一次临时股东会 会议资料 2026 年 2 月 27 日 | | | 2026 年第一次临时股东会会议须知 为维护元利化学集团股份有限公司（以下简称"公司"）全体股东的合法权 益，确保本次股东会的正常秩序和议事效率，保证股东会的顺利召开，根据《中 华人民共和国公司法》（以下简称"公司法"）、《中华人民共和国证券法》（以 下简称"证券法"）、中国证券监督管理委员会发布的《上市公司股东会规则》 及《元利化学集团股份有限公司章程》和《元利化学集团股份有限公司股东会议 事规则》等规定，特制订本次会议须知如下： 一、会议按照法律、法规、有关规定和公司章程、股东会议事规则的规定进 行，请参会人员自觉维护会议秩序，防止因不当行为影响其他股东合法权益。 二、为保证本次会议的严肃性和正常秩序，除出席会议的股东、董事、高级 管理人员、公司聘请律师外，公司有权依法拒绝其他人员入场。会议期间，请遵 守会场秩序，为保证每位参会股东的权益，谢绝个人录音、拍照及录像，对于干 扰会议秩序及其他股东合法权益的行为，公司有权予以制止并及时报告有关部门。 三、股东 ...